Illumina, Inc. (LON:0J8Z)
London
· Delayed Price · Currency is GBP · Price in USD 94.70
+0.66 (0.70%)
At close: Jun 27, 2025
Illumina Revenue
Illumina had revenue of $1.04B USD in the quarter ending March 30, 2025, a decrease of -3.25%. This brings the company's revenue in the last twelve months to $4.34B, down -3.47% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.34B
Revenue Growth
-3.47%
P/S Ratio
3.27
Revenue / Employee
$480.29K
Employees
9,030
Market Cap
10.94B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
| Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
| Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
| Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
| Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
Illumina News
- 4 days ago - Dr. Lal PathLabs boots genomics capabilities with Illumina’s NovaSeq™ X Series - Business Upturn
- 5 days ago - SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push - Benzinga
- 6 days ago - Standard BioTools jumps on sale of SomaLogic to Illumina - Seeking Alpha
- 6 days ago - Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy - PRNewsWire
- 11 days ago - Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling - Business Wire
- 18 days ago - lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - PRNewsWire
- 4 weeks ago - Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - PRNewsWire
- 4 weeks ago - Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript) - Seeking Alpha